Month: June 2026

In MedTech Insight, reporter Marion Webb takes readers inside Gothenburg’s GoCo Health Innovation City, exploring how the purpose‑built district is becoming a magnet for medtech, biotech and digital health companies. Webb’s piece highlights Sweden’s long‑standing strengths (deep academic–industry collaboration, strong government backing and a culture that encourages cross‑pollination between start‑ups and global players) and shows how GoCo is translating those advantages into a physical ecosystem designed for rapid innovation.

During her visit, Webb speaks with leaders from companies already embedded in GoCo, who describe how co‑location, shared infrastructure and proximity to AstraZeneca’s BioVentureHub are accelerating product development and clinical translation. The article underscores Gothenburg’s ambition to position itself as a European medtech powerhouse, with GoCo serving as both a community and a catalyst for next‑generation health technologies. Webb frames the district as a model for how intentional design, public–private partnership and concentrated expertise can reshape regional innovation capacity.

Read the full article here.

In a recent article featured in In Vivo, the CEO of Albus Health, Mikesh Udani, explores why nighttime physiology is still under‑represented in clinical evidence, and how that is beginning to change.

Overnight symptoms across respiratory, neurological, paediatric and cardiometabolic disease remain largely invisible to tools like diaries, morning recall and sleep‑lab assessments. Yet these signals often reflect treatment response, risk and disease biology.

The op‑ed highlights three shifts now reshaping evidence generation:
● Improvements in sleep and nighttime symptoms are emerging as a meaningful dimension of treatment response.
● Objective nighttime data is now achievable at scale. Entire nights of physiology no longer need to be compressed into a single morning entry.
● Passive, contactless remote monitoring is moving upstream into core study design.

The piece also points to the growing value of early‑warning signals such as passive detection of respiratory deterioration days before symptoms appear. This has implications far beyond respiratory disease, from oncology safety monitoring to neurological progression.

Read the full commentary here.